A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In two of three phase 3 trials, pirfenidone, an oral antifibrotic therapy, reduced disease progression, as measured by the decline in forced vital capacity (FVC) or vital capacity, in patients with idiopathic pulmonary fibrosis; in the third trial, this end point was not achieved. We sought to confirm the beneficial effect of pirfenidone on disease progression in such patients. METHODS: In this phase 3 study, we randomly assigned 555 patients with idiopathic pulmonary fibrosis to receive either oral pirfenidone (2403 mg per day) or placebo for 52 weeks. The primary end point was the change in FVC or death at week 52. Secondary end points were the 6-minute walk distance, progression-free survival, dyspnea, and death from any cause or from idiopathic pulmonary fibrosis. RESULTS: In the pirfenidone group, as compared with the placebo group, there was a relative reduction of 47.9% in the proportion of patients who had an absolute decline of 10 percentage points or more in the percentage of the predicted FVC or who died; there was also a relative increase of 132.5% in the proportion of patients with no decline in FVC (P<0.001). Pirfenidone reduced the decline in the 6-minute walk distance (P=0.04) and improved progression-free survival (P<0.001). There was no significant between-group difference in dyspnea scores (P=0.16) or in rates of death from any cause (P=0.10) or from idiopathic pulmonary fibrosis (P=0.23). However, in a prespecified pooled analysis incorporating results from two previous phase 3 trials, the between-group difference favoring pirfenidone was significant for death from any cause (P=0.01) and from idiopathic pulmonary fibrosis (P=0.006). Gastrointestinal and skin-related adverse events were more common in the pirfenidone group than in the placebo group but rarely led to treatment discontinuation. CONCLUSIONS: Pirfenidone, as compared with placebo, reduced disease progression, as reflected by lung function, exercise tolerance, and progression-free survival, in patients with idiopathic pulmonary fibrosis. Treatment was associated with an acceptable side-effect profile and fewer deaths. (Funded by InterMune; ASCEND ClinicalTrials.gov number, NCT01366209.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [191]
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“In three trials with doses that reached 2403 mg/day, pirfenidone effectively reduced FVC decline although had variable reductions in overall mortality and IPF-related mortality [12,13].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [45]
In the citing paper
“FVC is the gold-standard metric for assessing the lung function of patients with IPF and response to therapeutic intervention33–35.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [35]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationA sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
Self-citationDouble-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Azuma, A., Nukiwa, T., Tsuboi, E., Suga, M., Abe, S., Nakata, K., Taguchi, Y., Nagai, S., Itoh, H., Ohi, M., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-571oc · Cited by 954
Pirfenidone in idiopathic pulmonary fibrosis
Taniguchi, H., Ebina, M., Kondoh, Y., Ogura, T., Azuma, A., Suga, M., Taguchi, Y., Takahashi, H., Nakata, K., Sato, A., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00005209 · Cited by 946
Pirfenidone in idiopathic pulmonary fibrosis: Figure 1–
Swigris, J., & Fairclough, D. (2010) · European Respiratory Journal · doi:10.1183/09031936.00071710 · Cited by 799
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citationThe Clinical Course of Patients with Idiopathic Pulmonary Fibrosis
Martinez, F. J., Safrin, S., Weycker, D., Starko, K. M., Bradford, W. Z., King, T. E., Flaherty, K. R., Schwartz, D. A., Noble, P. W., Raghu, G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-12_part_1-200506210-00005 · Cited by 622
Self-citationKing, T. E., Albera, C., Bradford, W. Z., Costabel, U., Hormel, P., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., Thomeer, M., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60551-1 · Cited by 531
Self-citation
Cited by
Items 2,801–2,900 of 3,965
Lung Function Testing in Idiopathic Pulmonary Fibrosis: More Than Just Spirometry?
Casán, P., González, C. M., & Ancochea, J. (2016) · Archivos de Bronconeumología · doi:10.1016/j.arbr.2016.07.009 · Cited by 4
Galectin-3: Distant Biomarker or Relevant Target?
Keane, M. P. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201601-0192ed · Cited by 3
IPF in 2016: towards a better diagnosis
Spagnolo, P., Sverzellati, N., & Rossi, G. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30375-7 · Cited by 3
Kubo, N., Araki, K., Yamanaka, T., Hoshino, K., Ishii, N., Tsukagoshi, M., Igarashi, T., Watanabe, A., Hirai, K., Saitoh, F., et al. (2017) · Surgery Today · doi:10.1007/s00595-017-1489-7 · Cited by 3
Immunopathogenesis and Immune-based Therapy for Selected Autoimmune Disorders
Aribi, M. (2017) · InTech eBooks · doi:10.5772/63032 · Cited by 3
Biomarkers for Staging and Evaluating the Therapy for Idiopathic Pulmonary Fibrosis
Hara, Y., Shinkai, M., & Rubin, B. K. (2015) · Clinical Pulmonary Medicine · doi:10.1097/cpm.0000000000000111 · Cited by 4
Pitfalls in developing new compounds for idiopathic pulmonary fibrosis
Nathan, S. D., & Martínez, F. J. (2017) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000407 · Cited by 3
Self-citationBehr, J., Günther, A., Kreuter, M., Koschel, D., Prasse, A., Pfeifer, M. A., & Costabel, U. (2017) · Pneumologie · doi:10.1055/s-0043-109856 · Cited by 6
Lung Transplantation in Interstitial Lung Disease
Kim, C., CORDOVA, F. C., & Toyoda, Y. (2017) · Springer eBooks · doi:10.1007/978-3-319-49918-5_5 · Cited by 3
M24 Do antifibrotics impact on lung transplantation outcomes in idiopathic pulmonary fibrosis?
Huong, Y., Dhunnoo, V., Leonard, C. T., Venkateswaran, R., & Chaudhuri, N. (2017) · Thorax · doi:10.1136/thoraxjnl-2017-210983.446 · Cited by 3
Pulmonary Rehabilitation in Restrictive Thoracic Disorders
Holland, A. E., & Ambrosino, N. (2017) · Springer eBooks · doi:10.1007/978-3-319-65888-9_28 · Cited by 4
Baldi, B. G. (2017) · Jornal Brasileiro de Pneumologia · doi:10.1590/s1806-37562017000060003 · Cited by 5
Gotfried, M. H., Girod, C. E., Antin-Ozerkis, D. E., Burgess, T., Strombom, I., Stauffer, J. L., Kirchgaessler, K.-U., & Padilla, M. L. (2018) · Pulmonary Therapy · doi:10.1007/s41030-018-0053-y · Cited by 3
Pharmacologic Treatment of IPF
Smargiassi, A., Pasciuto, G., Conte, E. G., Andreani, M., Marra, R., & Richeldi, L. (2018) · Respiratory medicine · doi:10.1007/978-3-319-99975-3_13 · Cited by 3
Li, S., Lin, Y., & Liang, S. (2019) · Medicine · doi:10.1097/md.0000000000015407 · Cited by 4
Hollin, I. L., Dimmock, A. E. F., Bridges, J. F. P., Danoff, S. K., & Bascom, R. (2019) · Patient Preference and Adherence · doi:10.2147/ppa.s201632 · Cited by 4
Diagnosis and treatment of interstitial lung disease: focusing on idiopathic pulmonary fibrosis
Kang, H.-R., & Choi, S. M. (2020) · Journal of Korean Medical Association · doi:10.5124/jkma.2020.63.3.159 · Cited by 3
Suzuki, A., Sakaguchi, H., Sakamoto, K., Ebina, M., Azuma, A., Ogura, T., Taguchi, Y., Suga, M., Takahashi, H., Sugiyama, Y., et al. (2021) · CHEST Journal · doi:10.1016/j.chest.2021.05.058 · Cited by 4
Interstitial lung disease on the acute take for the non-respiratory physician
Yioe, V., Phillips, G., & Spencer, L. G. (2021) · Clinical Medicine · doi:10.7861/clinmed.2021-0694 · Cited by 3
Cottin, V., Crestani, B., Cadranel, J. L., Cordier, J. F., Marchand-Adam, S., Prévôt, G., Wallaert, B., Bergot, E., Camus, P., Dalphin, J., et al. (2017) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2017.07.019 · Cited by 4
“2403 mg/j) à celui du placebo, administrés pendant 2 semaines, chez 555 patients [41].”
BackgroundMethodInfluentialOutpatient Pharmacologic Management of Lung Transplant Candidates on the Waiting List
Sayah, D. M., & Pilewski, J. M. (2022) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2022.01.002 · Cited by 4
Guo, R., Zhou, Y., Lin, F., Li, M., Tan, C., & Xu, B. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.981604 · Cited by 4
“Patients with IPF from COVID-19 infection had a much worse prognosis and faced complex complications even after recovery from COVID-19 (King et al., 2014; George et al., 2020; Sun et al., 2020).”
BackgroundLederer, C., Buschulte, K., Hellmich, B., Heußel, C. P., Kriegsmann, M., Polke, M., & Kreuter, M. (2023) · Die Innere Medizin · doi:10.1007/s00108-023-01476-3 · Cited by 7
Nanotherapeutic Approaches to Treat COVID-19-Induced Pulmonary Fibrosis
Kanvinde, S., Deodhar, S., Kulkarni, T. A., & Jogdeo, C. M. (2023) · BioTech · doi:10.3390/biotech12020034 · Cited by 3
“The ASCEND study enrolled patients with high risk of disease progression [15].”
MethodTreatment of Idiopathic Pulmonary Fibrosis
Nathan, S. D., Brown, A. W., & King, C. S. (2016) · Springer eBooks · doi:10.1007/978-3-319-32794-5_7 · Cited by 4
Self-citationSystematic review of content and quality of idiopathic pulmonary fibrosis review articles
Milne, K. M., Chan, C., Fisher, J. H., de Boer, K., & Ryerson, C. J. (2018) · ERJ Open Research · doi:10.1183/23120541.00156-2018 · Cited by 3
Idiopathic Pulmonary Fibrosis: The Epidemiology and Natural History of Disease
Mohning, M. P., Swigris, J. J., & Olson, A. L. (2018) · Respiratory medicine · doi:10.1007/978-3-319-99975-3_2 · Cited by 2
Self-citationBlood-based Diagnosis of Idiopathic Pulmonary Fibrosis. Fantasy or Reality?
Maher, T. M. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201606-1128ed · Cited by 3
Lung Function in Asthma, Chronic Obstructive Pulmonary Disease, and Lung Fibrosis
Janssens, W., & Bleyenbergh, P. V. (2020) · Wiley eBooks · doi:10.1002/9781118597309.ch37 · Cited by 5
Interstitial Pneumonia With Autoimmune Features
Graney, B. A., & Fischer, A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.11360-1 · Cited by 5
Hypoxia-inducible factor-2 (HIF2) regulates alveolar regeneration after repetitive injuryPreprint
McCall, A. S., Tanjore, H., Burman, A., Sherrill, T. P., Chapman, M., Calvi, C. L., Camarata, J. E., Hunt, R. P., Nichols, D. S., Banovich, N. E., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.17.557477 · Cited by 3
Liu, Y., Habibie, H., Borghuis, T., Liu, G., Hansbro, P. M., Melgert, B. N., & Burgess, J. K. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.05.626371 · Cited by 2
Hoffman, E. T., Barboza, W. R., Rodriguez, L. R., Dherwani, R., Tomer, Y., Murthy, A., Bennett, A., Nottingham, A. N., Babu, A., Chavez, K., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.06.17.599351 · Cited by 6
Ziehr, D. R., Li, F., Parnell, K. M., Krah, N. M., Leahy, K. J., Guillermier, C., Gao, C., Prell, S. A., Vigder, N., Poli, S., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.ads2673 · Cited by 17
Park, J. H., Jang, J. H., Kim, H. K., Jang, H. J., Lee, S., Kim, S.-H., Kim, J. Y., Choi, H. E., Han, J., Kim, D., et al. (2022) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2022.0031 · Cited by 3
Idiopathic pulmonary fibrosis: a clinical case of long-term follow-up
Ignatova, G. L., Blinova, E. V., Belsner, M. S., & Korotkaya, M. A. (2022) · Consilium Medicum · doi:10.26442/20751753.2022.9.201962 · Cited by 2
Transcriptional factor RUNX1: A potential therapeutic target for fibrotic pulmonary disease
LIU, J., WANG, F., YUAN, B., & Luo, F. (2023) · Biocell · doi:10.32604/biocell.2023.026148 · Cited by 3
Comparing the Utilization of Antifibrotic Medications Based on Income Level
Dempsey, T. M., Thao, V., Helfinstine, D. A., Sangaralingham, L. R., & LIMPER, A. H. (2023) · CHEST Journal · doi:10.1016/j.chest.2023.07.4215 · Cited by 2
Lung Transplantation: Selection of Candidates
Thomas, C., Williams, M., & Shlobin, O. A. (2023) · OBM Transplantation · doi:10.21926/obm.transplant.2304197 · Cited by 2
Sun, S., Wang, Y., & Feng, J. (2025) · Hereditas · doi:10.1186/s41065-025-00401-y · Cited by 3
Pei, X., Zheng, F., Li, Y., Li, X., Lin, Z., Han, X., Tian, Z., Cao, K., Ren, D., & Li, C. (2025) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2025.103588 · Cited by 3
Enomoto, T., Takeda, Y., Shirai, Y., Hasegawa, T., Zhao, F., Lunding, H. B., Pohl, M., Edahiro, R., Shichino, S., Kawasaki, T., et al. (2025) · Respiratory Research · doi:10.1186/s12931-025-03237-2 · Cited by 2
An Elastase Inhibitor ShSPI from Centipede Attenuates Bleomycin-Induced Pulmonary Fibrosis
Lian, X., Liu, B., Li, D., Wang, X., Long, C., Feng, X., Liao, Q., & Rong, M. (2025) · Toxins · doi:10.3390/toxins17050213 · Cited by 2
“Currently, the two main drugs for IPF treatment, pirfenidone and nintedanib, can only delay the progression of the disease and do not provide a complete cure [16].”
Idiopathic pleuroparenchymal fibroelastosis: diagnosis and management
Ishii, H., Kinoshita, Y., Hamada, N., Fujita, M., & Kushima, H. (2025) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2025.2499651 · Cited by 3
Yao, L., Liu, B., & Wang, Y. (2025) · Scientific Reports · doi:10.1038/s41598-025-01759-9 · Cited by 2
Lu, F., Wang, G., Yang, X., Luo, J., Ma, H., Pan, L., Yao, Y., & Xie, K. (2025) · Pharmaceuticals · doi:10.3390/ph18060859 · Cited by 5
“Currently available pharmacological treatments, such as Nintedanib and Pirfenidone, exhibit only limited effectiveness in slowing the progression of the disease [3,4].”
Emerging Concepts in Therapeutic Interventions for Idiopathic Pulmonary Fibrosis
Schott, C. A., Mohning, M. P., & Cooley, J. C. (2025) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/a-2651-1937 · Cited by 7
Chen, L., Chen, H., Chen, Z., Zhang, K., Zhang, H., Xu, J., & Chen, T. (2025) · Scientific Reports · doi:10.1038/s41598-025-12046-y · Cited by 4
Points to consider in the management of ANCA-associated vasculitis
Papadopoulou, M., & Καραμανάκος, Α. (2025) · Autoimmunity Reviews · doi:10.1016/j.autrev.2025.103894 · Cited by 2
Srivali, N., Giacomi, F. D., Moua, T., & Ryu, J. H. (2025) · Heart & Lung · doi:10.1016/j.hrtlng.2025.08.002 · Cited by 4
Dimić-Janjić, S., Stjepanović, M., Belić, S., Vukosavljević, D., Milivojević, I., Trboljevac, N., Nikolić, N., Stamenić, S., Stojanović, M., Stosic, K., et al. (2025) · Diagnostics · doi:10.3390/diagnostics15172121 · Cited by 3
“Currently, there is no definitive cure for IPF; however, advancements in pharmacotherapy, particularly the use of antifibrotic agents, aim to mitigate symptoms and slow disease progression, thereby enhancing patients’ quality of life [10,11].”
LTI-03 peptide demonstrates anti-fibrotic activity in ex vivo lung slices from patients with IPF
MacKenzie, B., Mahavadi, P., Pinho Jannini-Sa, Y. A., Creyns, B., Coelho, A. L., Espindola, M., Ruppert, C., Windsor, B., Aigner, C., Hogaboam, C. M., et al. (2025) · iScience · doi:10.1016/j.isci.2025.113437 · Cited by 2
Nick, P. L.-K., Studnicka, M., Gregor, J., Ovesná, P., Vašáková, M., Simmons, W., Li, Y., Strek, M. E., Li, P., Snyder, L. D., et al. (2025) · ERJ Open Research · doi:10.1183/23120541.00402-2025 · Cited by 3
Pathophysiological Insights and Clinical Management Strategies for Interstitial Lung Diseases
Tian, L., Wang, Y., Qi, W., Wang, B., Zhang, X., Gong, M., Zhang, X., & Wang, T. (2025) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2025.003 · Cited by 4
Andugulapati, S. B., Kambhampati, V., & Kumar, H. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00322 · Cited by 2
Bolger, G. B. (2025) · Life · doi:10.3390/life15101600 · Cited by 6
“Pirfenidone, the first agent to be developed specifically for fibrotic lung disease, has been shown on the basis of multiple phase 3 trials to be safe and effective in both IPF and PPF [68–71].”
Shah, A., Lopez, E. K., Geller, A., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13102522 · Cited by 2
“Antifibrotics such as nintedanib and pirfenidone have been considered, given that they have shown survival benefits in patients with isolated PF [9,10].”
InfluentialThe role of epigenetic regulation in idiopathic pulmonary fibrosis
Li, R. M., Stentenbach, M., Tan, D. B. A., Ludewick, H. P., Walters, E. H., Clynick, B., & Moodley, Y. P. (2025) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00030.2025 · Cited by 3
Classification of interstitial pneumonias: ready for the future or stuck in the past?
Kolb, M. R. J., Cottin, V., & Crestani, B. (2025) · European Respiratory Journal · doi:10.1183/13993003.01845-2025 · Cited by 2
Snoeck, H. (2025) · European Respiratory Journal · doi:10.1183/13993003.02083-2025 · Cited by 6
Downregulation of SLC40A1 leads to iron accumulation in fibrotic lung fibroblasts
Dang, Q., Huang, C., Liang, Y., Surendran, A. M., Muthiah, D., Vaddadi, K., Hewawasam, S., Mills, T. W., & Liu, L. (2026) · Respiratory Research · doi:10.1186/s12931-025-03479-0 · Cited by 3
Moon, J. Y., Beenken, M. J., & Moua, T. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15031051 · Cited by 4
“Few treatments have directly impacted presenting symptoms or loss of respiratory-related quality of life [1,3,4].”
Maddali, M. V., Pugashetti, J. V., Pienkos, S. M., Moore, A. R., Konkol, S., Kim, J. S., Ma, S.-F., Newton, C. A., Garcia, C. K., Adegunsoye, A., et al. (2026) · American Journal of Respiratory and Critical Care Medicine · doi:10.1093/ajrccm/aamag006 · Cited by 3
Liang, H., Lang, Q., Liang, Z., & Sun, J. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s568106 · Cited by 3
Interstitial lung abnormalities: to treat or not to treat? The hamlet dilemma
Zanini, U., Franco, G., Pirotta, C., Passeri, E., Mazzotta, S. M., Ferrara, G., Mura, M., Faverio, P., & Luppi, F. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1762243 · Cited by 2
Yang, Q., Xie, C., Luo, Z., Huang, W., Zhang, Z., Ren, K., Xu, X., HE, H., He, M., & Yin, L. (2026) · Redox Report · doi:10.1080/13510002.2026.2632434 · Cited by 4
Standalone prognostication of idiopathic pulmonary fibrosis using attention-based deep learning
Lee, J. H., Chae, K. J., Lee, H. S., Park, J., Choi, S. M., Goo, J. M., & Kim, H. (2026) · American Journal of Respiratory and Critical Care Medicine · doi:10.1093/ajrccm/aamag098 · Cited by 3
Nagre, N. N., Srinivas, B., Richards, N., Washington, R., Nicholson, G., Sanders, Y. Y., Kośmider, B., & Matrougui, K. (2026) · Redox Biology · doi:10.1016/j.redox.2026.104117 · Cited by 4
Zheng, J., Du, H., Ni, H., Liu, M., Yu, Z., Dong, Y., & Guo, Y. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.116511 · Cited by 2
RetractedTargeting the epithelium in pulmonary fibrosis
Lizé, M., Mayr, C. H., Bleck, M., Wollin, L., Wohnhaas, C. T., Shalashova, I., Olbrich, H., Heilker, R., Engler, A., Bammert, M., et al. (2026) · European Respiratory Review · doi:10.1183/16000617.0225-2025 · Cited by 5
Poletti, V. E., Ryerson, C. J., & Piciucchi, S. (2026) · European Respiratory Journal · doi:10.1183/13993003.01903-2025 · Cited by 2
Wang, Y., Peng, X., Chen, J., Zhang, Y., Zhang, T., Zhang, J., Fan, J., Zheng, H., Liu, Q., Song, Z., et al. (2026) · Advanced Science · doi:10.1002/advs.202515581 · Cited by 3
Solomon, J. J., Dieudé, P., Matson, S. M., Lee, J. S., Rojas‐Serrano, J., Sebastiani, M., Gonzalez, A., Demoruelle, M. K., Hoffman‐Vold, A., Kam, M. L. W., et al. (2026) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(26)00094-9 · Cited by 12
Self-citationProgressive pulmonary fibrosis: a state-of-the-art review
Cottin, V., Brown, K. K., Flaherty, K. R., Kolb, M. R. J., Lynch, D. A., Oldham, J. M., Valenzuela, C., Wijsenbeek, M. S., & Wells, A. U. (2026) · European Respiratory Journal · doi:10.1183/13993003.01557-2025 · Cited by 4
Systemische Sklerose: Was ist gesichert in der Therapie?
Becker, M. O. (2016) · Der Internist · doi:10.1007/s00108-016-0148-1 · Cited by 2
Toward understanding patient experience in idiopathic pulmonary fibrosis
Danoff, S. K. (2017) · European Respiratory Journal · doi:10.1183/13993003.02202-2016 · Cited by 2
Survival in Idiopathic Pulmonary Fibrosis: Perspectives from Pulmonary Arterial Hypertension
Maher, T. M., Dejonckheere, F., & Nathan, S. D. (2017) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2017.23.3-b.s3 · Cited by 2
Self-citationMoon, R., Barker, E., Agnew, S., Sutcliffe, J., Kwok, A., & Spencer, L. (2017) · Thorax · doi:10.1136/thoraxjnl-2017-210983.447 · Cited by 1
Troy, L. K. (2018) · Respirology · doi:10.1111/resp.13274 · Cited by 2
Ambulatory oxygen and quality of life in interstitial lung disease
Page, D. B., & Thannickal, V. J. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30337-0 · Cited by 2
Planté-Bordeneuve, T., Haouas, H., Vanderheyde, K., & Froidure, A. (2018) · Acta Clinica Belgica · doi:10.1080/17843286.2018.1545375 · Cited by 2
Case 10-2019: A 69-Year-Old Man with Progressive Dyspnea
Black, K. E., Montesi, S. B., Feneis, J. F., & Mark, E. J. (2019) · New England Journal of Medicine · doi:10.1056/nejmcpc1900143 · Cited by 2
Weikert, T., Sommer, G., Tamm, M., Haegler, P., Cyriac, J., Sauter, A. W., Hostettler, K., & Bremerich, J. (2019) · European Journal of Radiology · doi:10.1016/j.ejrad.2019.108719 · Cited by 2
Smallwood, N., & Goh, N. S. L. (2021) · doi:10.1093/med/9780198821328.003.0090 · Cited by 2
Challenges in the Diagnosis and Management of Patients with Fibrosing Interstitial Lung Disease
Tolle, L. B. (2022) · Case Reports in Pulmonology · doi:10.1155/2022/9942432 · Cited by 5
Ameliorative effects of pirfenidone in chronic kidney disease
Ghodrati, S., Haghi, Y. R., Baharani, J., et al. (2022) · Journal of Nephropharmacology · doi:10.34172/npj.2022.10458 · Cited by 2
Zhou, L., Tian, H., Wang, Q., Xiong, W., Zhou, X., & Yan, J. (2022) · PubMed · Cited by 2
Lee, J. H., Jang, J. H., Park, J. H., et al. (2023) · Medicine · doi:10.1097/md.0000000000032786 · Cited by 2
“[5] Previous major trials demonstrating the effect of anti-fibrotic drugs to contribute to food and drug administration approval have not reported data on the impact of treatment on cough.[6,7] Although some studies show efficacy”
BackgroundEpigenetics of the pathogenic myofibroblast in lung disease
Bernau, K., Sandbo, N. K., & Brasier, A. R. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-823931-5.00018-9 · Cited by 2
Ma, M., Cao, M., Gao, Y., Qiu, X., Jiang, H., & Cai, H. (2023) · Medicine · doi:10.1097/md.0000000000033722 · Cited by 2
Ballesteros, B. L.-M., López‐de‐Andrés, A., Jiménez‐García, R., Zamorano‐León, J. J., Carabantes-Alarcón, D., Cuadrado‐Corrales, N., del-Barrio, J. L., Pérez‐Farinós, N., & de Miguel‐Díez, J. (2023) · Healthcare · doi:10.3390/healthcare11111534 · Cited by 2
Les cryobiopsies pulmonaires transbronchiques dans les pneumopathies infiltrantes diffuses
Ménigoz, C., Dirou, S., Sagan, C., Corne, F., Moui, A., Defrance, C., Liberge, R., Morla, O., Patarin, V., Nicolas, A., et al. (2023) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2023.04.003 · Cited by 4
Biogenesis and Function of circRNAs in Pulmonary Fibrosis
Zhang, S., Hu, W., Lv, C., & Song, X. (2024) · Current Gene Therapy · doi:10.2174/0115665232284076240207073542 · Cited by 3
Chen, C., Kolbe, J., Paton, J. F. R., & Fisher, J. P. (2024) · Respiratory Medicine and Research · doi:10.1016/j.resmer.2024.101103 · Cited by 2
Pirfenidone ameliorates alcohol-induced promotion of breast cancer in mice
Li, H., Xu, M., Chen, D., Wen, W., & Luo, J. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1351839 · Cited by 4
Efficacy and safety of pirfenidone according to clinical trials
Хохлов, А. Л., & Rybachkova, J. V. (2024) · Patient-Oriented Medicine and Pharmacy · doi:10.37489/2949-1924-0036 · Cited by 2
Integrating the assessment of quality of life in care and research in pulmonary fibrosis
Aronson, K. I., Swigris, J. J., & Wijsenbeek, M. S. (2024) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001095 · Cited by 3
Self-citation“Bubbly lung”, a honeycombing variant with more favorable outcome
Tzilas, V., Hartman, T. E., Charokopos, A., Decker, P. A., & Ryu, J. H. (2024) · Respiratory Investigation · doi:10.1016/j.resinv.2024.08.012 · Cited by 2
An Eternal Dilemma: Exposing the Impact of Immortal Time Bias on Antifibrotic Effectiveness
Kyle, A. R., & Dempsey, T. M. (2024) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202407-717ed · Cited by 2
Carlson, L., Kalafatis, D., Pesonen, I., Magnusson, J. M., & Sköld, M. C. (2024) · Chronic Respiratory Disease · doi:10.1177/14799731241299443 · Cited by 3
Metadata
- Authors
- King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., Lederer, D. J., Nathan, S. D., Pereira, C. A., Sahn, S. A., Sussman, R., Swigris, J. J., & Noble, P. W.
- Affiliations
- Cedars-Sinai Medical Center (US)
- The Alfred Hospital (AU)
- University of Miami (US)
- Prince Charles Hospital (AU)
- Vanderbilt University Medical Center (US)
- Columbia University Irving Medical Center (US)
- Inova Fairfax Hospital (US)
- Universidade Federal de São Paulo (BR)
- Medical University of South Carolina (US)
- Overlook Medical Center (US)
- National Jewish Health (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2083-2092
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2168666423
- Cited by
- 3,975
- References
- 27
- Citations by year
- 2026: 272 · 2025: 303 · 2024: 371 · 2023: 315 · 2022: 339 · 2021: 412 · 2020: 343 · 2019: 310 · 2018: 335 · 2017: 319 · 2016: 288 · 2015: 279 · 2014: 76
- FWCI
- 256.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UNIFESP Institutional Repository (Universidade Federal de São Paulo) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- pirfenidone, idiopathic pulmonary fibrosis, antifibrotic therapy, forced vital capacity decline, disease progression, mortality, progression-free survival, 6-minute walk distance, dyspnea, gastrointestinal adverse effects, cutaneous adverse events, exercise tolerance, lung function decline, safety and tolerability
- MeSH terms
- Administration, Oral, Adult, Aged, Aged, 80 and over, Antifibrinolytic Agents, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Male, Middle Aged, Pyridones, Vital Capacity, Treatment Outcome, Disease Progression, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.